BRAF and cutaneous melanoma: For example, TAK-733 has demonstrated activity against multiple cutaneous melanoma cell lines, with a high proportion of BRAF V600E-mutant cell lines showing high sensitivity (IC50 < 0.1 μM) and with no statistically significant association between BRAF status and response [25], and against uveal melanoma cell lines [26].